Leerink Partners Issues Positive Forecast for Medline (NASDAQ:MDLN) Stock Price

Medline (NASDAQ:MDLN) had its price target lifted by stock analysts at Leerink Partners from $43.00 to $46.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners‘s price objective points to a potential upside of 15.00% from the company’s previous close.

Other equities research analysts also recently issued research reports about the stock. Weiss Ratings downgraded shares of Medline from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, October 8th. BTIG Research restated a “buy” rating and issued a $55.00 target price on shares of Medline in a research note on Thursday. Stifel Nicolaus lowered their target price on Medline from $50.00 to $45.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Bank of America dropped their price target on Medline from $53.00 to $46.00 in a research report on Thursday, August 6th. Finally, Citigroup upgraded Medline to a “strong-buy” rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.15.

Medline Stock Performance

Medline stock traded down $0.35 during mid-day trading on Thursday, reaching $40.00. The company’s stock had a trading volume of 7,943,589 shares, compared to its average volume of 7,748,465. The firm has a market cap of $52.59 billion and a price-to-earnings ratio of 50.51. The business has a 50 day moving average price of $34.58 and a 200-day moving average price of $39.53. The company has a current ratio of 4.33, a quick ratio of 2.61 and a debt-to-equity ratio of 0.66. Medline has a twelve month low of $31.37 and a twelve month high of $50.88.

Medline (NASDAQ:MDLN) last issued its earnings results on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.12. The business had revenue of $7.86 billion for the quarter. Sell-side analysts predict that Medline will post 1.49 EPS for the current fiscal year.

Insider Activity at Medline

In other news, major shareholder Private Ltd Gic sold 2,570,999 shares of the firm’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $35.35, for a total transaction of $90,884,814.65. Following the transaction, the insider directly owned 20,231,483 shares of the company’s stock, valued at approximately $715,182,924.05. This trade represents a 11.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 8,538,960 shares of company stock worth $302,807,442 over the last quarter. 0.81% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Medline

A number of institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in Medline by 68.3% during the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock valued at $25,000 after buying an additional 254 shares in the last quarter. Whipplewood Advisors LLC acquired a new position in Medline during the first quarter worth about $30,000. Reyes Financial Architecture Inc. bought a new stake in Medline in the third quarter worth about $30,000. NewEdge Advisors LLC raised its position in Medline by 100.0% in the second quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock worth $37,000 after acquiring an additional 475 shares in the last quarter. Finally, Allworth Financial LP lifted its holdings in Medline by 86.2% in the 2nd quarter. Allworth Financial LP now owns 1,052 shares of the company’s stock valued at $41,000 after acquiring an additional 487 shares during the last quarter.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline earned $0.44 per share, above the $0.32 consensus, on revenue of $7.86 billion. Reports also highlighted improved full-year growth expectations, although the company reaffirmed its adjusted EBITDA outlook. Medline Q3 2026 earnings
• Positive Sentiment: The company plans to repurchase $1 billion of shares, which could support per-share results and signal confidence in its business. Q3 beat and share buybacks
• Positive Sentiment: BTIG reaffirmed its Buy rating and set a $55 price target, implying substantial upside from the cited share price. Barclays also issued a Buy rating, adding to favorable analyst sentiment. Barclays rating
• Neutral Sentiment: Medline plans 2027 price increases to offset inflation. The move may help protect margins, but its impact will depend on customers’ ability and willingness to absorb higher prices. Pricing plans and Q3 results
• Negative Sentiment: A law firm announced an investigation into potential securities-fraud claims related to alleged product-quality issues and prior stock declines. The announcement is not a finding of wrongdoing, but the matter could create legal and reputational risk. Securities investigation announcement

About Medline

Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.

Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.